Immunomodulators and immunosuppressants for progressive multiple sclerosis: a network meta-analysis - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/39254048/
The number of people with PMS with relapses is probably slightly reduced with rituximab at two years, and interferon beta-1b at three years, compared to placebo. Both drugs are also...
This network meta-analysis evaluated 23 studies on treatments for progressive multiple sclerosis, finding limited evidence on efficacy and safety, with rituximab and interferon beta-1b showing slight relapse reduction compared to placebo.
Temporal Relationship Between Serum Neurofilament Light Chain and Radiologic Disease Activity in Patients With Multiple Sclerosis - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/38648580/
Although sNfL correlated with the presence of Gd+ lesions, most participants with Gd+ lesions did not have elevations in sNfL levels. These observations have implications for the use and interpretation...
In the RESTORE trial, serum neurofilament light chain (sNfL) levels correlated with gadolinium-enhancing lesions in MS, but most patients with lesions showed no significant sNfL elevation, complicating its use as a biomarker.
Natalizumab reduces loss of gray matter and thalamic volume in patients with relapsing-remitting multiple sclerosis: A post hoc analysis from the randomized, placebo-controlled AFFIRM trial - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/38469809/
NCT00027300URL: https://clinicaltrials.gov/ct2/show/NCT00027300.
Natalizumab significantly reduces gray matter and thalamic atrophy in relapsing-remitting multiple sclerosis patients, with 64.3% less gray matter loss and 57.0% less thalamic volume loss compared to placebo.
MS treatment de-escalation: review and commentary - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/39093335/
Almost all currently licensed disease-modifying therapies (DMTs) for MS treatment require prolonged if not lifelong administration. Yet, as people age, the immune system has increasingly reduced responsiveness, known as immunosenescence....
De-escalation of MS disease-modifying therapies in older patients may maintain efficacy while reducing risks, but larger, longer studies are needed to confirm safety and effectiveness across age groups.
Adverse effects of immunotherapies for multiple sclerosis: a network meta-analysis - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/38032059/
We found mostly low and very low-certainty evidence that drugs used to treat MS may not increase SAEs, but may increase withdrawals compared with placebo. The results suggest that there...
This study compared adverse effects of multiple sclerosis immunotherapies through network meta-analyses, highlighting varying safety profiles, with low-certainty evidence for drug rankings and significant withdrawal rates due to adverse events.